Knockdown of type I insulin-like growth factor receptor inhibits human colorectal cancer cell growth and downstream PI3K/Akt, WNT/β-catenin signal pathways

Biomedicine and Pharmacotherapy

Volumn 73, Issue , 2015, Pages 12-18

  Zhang, Qian yun ^a   Wang, Lu ^a   Song, Zhi yu ^a   Qu, Xian jun ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Apoptosis; Cell cycle arrest; IGF1R; Inflammation; PI3K Akt; WNT catenin

Indexed keywords

BETA CATENIN; CYCLOOXYGENASE 2; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P53; SMALL INTERFERING RNA; SOMATOMEDIN C RECEPTOR; WNT PROTEIN; IGF1R PROTEIN, HUMAN; SOMATOMEDIN RECEPTOR;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE REGULATION; COLONY FORMATION; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; HT 29 CELL LINE; HUMAN; HUMAN CELL; INFLAMMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; WNT SIGNALING PATHWAY; CELL PROLIFERATION; COLORECTAL TUMOR; DEFICIENCY; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

BETA CATENIN; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; GENE KNOCKDOWN TECHNIQUES; HT29 CELLS; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTORS, SOMATOMEDIN; WNT SIGNALING PATHWAY;

EID: 84937795711     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2015.05.004     Document Type: Article

References (43)

1. Fearnhead N.S., Britton M.P., Bodmer W.F. The ABC of APC. Hum. Mol. Genet. 2001, 10:721-733.
2. Su V.B., Kinzler L.K.K.W. Association of the APC tumor suppressor protein with catenins. Science 1993, 262(5140):1734-1737.
3. Rubinfeld B., Souza B., Albert I., Muller O., Chamberlain S.H., Masiarz F.R., et al. Association of the APC gene product with beta-catenin. Science 1993, 262:1731-1734.
4. Papkoff J., Brown A.M., Varmus H.E. The int-1 proto-oncogene products are glycoproteins that appear to enter the secretory pathway. Mol. Cell. Biol. 1987, 7:3978-3984.
5. Anastas J.N., Moon R.T. WNT signalling pathways as therapeutic targets in cancer. Nat. Rev. Cancer 2013, 13:11-26.
6. Noubissi F.K., Elcheva I., Bhatia N., Shakoori A., Ougolkov A., Liu J., et al. CRD-BP mediates stabilization of [beta]TrCP1 and c-myc mRNA in response to [beta]-catenin signalling. Nature 2006, 441:898-901.
7. van de Wetering M., Sancho E., Verweij C., de Lau W., Oving I., Hurlstone A., et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002, 111:241-250.
8. Le Roith D. Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. New Engl. J. Med. 1997, 336:633-640.
9. Tao Y., Pinzi V., Bourhis J., Deutsch E. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway - therapeutic perspectives in cancer. Nat. Clin. Pract. Oncol. 2007, 4:591-602.
10. Rosenzweig S.A., Atreya H.S. Defining the pathway to insulin-like growth factor system targeting in cancer. Biochem. Pharmacol. 2010, 80:1115-1124.
11. Fürstenberger G., Senn H.-J. Insulin-like growth factors and cancer. Lancet Oncol. 2002, 3:298-302.
12. Ewing G.P., Goff L.W. The insulin-like growth factor signaling pathway as a target for treatment of colorectal carcinoma. Clin. Colorectal Cancer 2010, 9:219-223.
13. Tricoli J.V., Rall L.B., Karakousis C.P., Herrera L., Petrelli N.J., Bell G.I., et al. Enhanced levels of insulin-like growth factor messenger RNA in human colon carcinomas and liposarcomas. Cancer Res. 1986, 46:6169-6173.
14. Knowlden J.M., Jones H.E., Barrow D., Gee J.M., Nicholson R.I., Hutcheson I.R. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for gefitinib ("Iressa") response and resistance. Breast Cancer Res. Treat. 2008, 111:79-91.
15. Daughaday W.H., Rotwein P., Insulin-like growth factors I., Peptide I.I. messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocrine Rev. 1989, 10:68-91.
16. Sekharam M., Zhao H., Sun M., Fang Q., Zhang Q., Yuan Z., et al. Insulin-like growth factor 1 receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt/Bcl-x(L) pathway. Cancer Res. 2003, 63:7708-7716.
17. Haisa M. The type 1 insulin-like growth factor receptor signalling system and targeted tyrosine kinase inhibition in cancer. J. Int. Med. Res. 2013, 41:253-264.
18. Choo K.B., Soon Y.L., Nguyen P.N., Hiew M.S., Huang C.J. MicroRNA-5p and -3p co-expression and cross-targeting in colon cancer cells. J. Biomed. Sci. 2014, 21:95.
19. Sakai H., Sato A., Aihara Y., Ikarashi Y., Midorikawa Y., Kracht M., et al. MKK7 mediates miR-493-dependent suppression of liver metastasis of colon cancer cells. Cancer Sci. 2014, 105:425-430.
20. Guo S.T., Jiang C.C., Wang G.P., Li Y.P., Wang C.Y., Guo X.Y., et al. MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer. Oncogene 2013, 32:1910-1920.
21. Vanamala J., Reddivari L., Radhakrishnan S., Tarver C. Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways. BMC Cancer 2010, 10:238.
22. Li X.X., Huang L.Y., Peng J.J., Liang L., Shi D.B., Zheng H.T., et al. Klotho suppresses growth and invasion of colon cancer cells through inhibition of IGF1R-mediated PI3K/AKT pathway. Int. J. Oncol. 2014, 45:611-618.
23. Coussens L.M., Zitvogel L., Palucka A.K. Neutralizing tumor-promoting chronic inflammation: a magic bullet?. Science 2013, 339:286-291.
24. Lakatos P.L., Lakatos L. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J. Gastroenterol. 2008, 14:3937-3947.
25. Askling J., Dickman P.W., Karlen P., Brostrom O., Lapidus A., Lofberg R., et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology 2001, 120:1356-1362.
26. Atreya I., Neurath M.F. Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies. Exp. Rev. Anticancer Ther. 2008, 8:561-572.
27. Waldner M.J., Neurath M.F. Cytokines in colitis associated cancer: potential drug targets?. Inflamm. Allergy Drug Targets 2008, 7:187-194.
28. Hong S.H., Avis I., Vos M.D., Martínez A., Treston A.M., Mulshine J.L. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. Cancer Res. 1999, 59:2223-2228.
29. Labayle D., Fischer D., Vielh P., Drouhin F., Pariente A., Bories C., et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991, 101:635-639.
30. Giardiello F.M., Hamilton S.R., Krush A.J., Piantadosi S., Hylind L.M., Celano P., et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. New Engl. J. Med. 1993, 328:1313-1316.
31. Phillips R.K., Wallace M.H., Lynch P.M., Hawk E., Gordon G.B., Saunders B.P., et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002, 50:857-860.
32. Steinbach G., Lynch P.M., Phillips R.K., Wallace M.H., Hawk E., Gordon G.B., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. New Engl. J. Med. 2000, 342:1946-1952.
33. Studer R.K., Levicoff E., Georgescu H., Miller L., Jaffurs D., Evans C.H. Nitric oxide inhibits chondrocyte response to IGF-I: inhibition of IGF-IRbeta tyrosine phosphorylation,. Am. J. Physiol. Cell Physiol. 2000, 279:C961-C969.
34. Lee H., Kim S.R., Oh Y., Cho S.H., Schleimer R.P., Lee Y.C. Targeting insulin-like growth factor-I and insulin-like growth factor-binding protein-3 signaling pathways. A novel therapeutic approach for asthma. Am. J. Resp. Cell Mol. Biol. 2014, 50:667-677.
35. Puzik A., Rupp J., Troger B., Gopel W., Herting E., Hartel C. Insulin-like growth factor-I regulates the neonatal immune response in infection and maturation by suppression of IFN-gamma. Cytokine 2012, 60:369-376.
36. Suh H.S., Zhao M.L., Derico L., Choi N., Lee S.C. Insulin-like growth factor 1 and 2 (IGF1, IGF2) expression in human microglia: differential regulation by inflammatory mediators. J. Neuroinflammation 2013, 10:37.
37. Harper C.E., Patel B.B., Wang J., Eltoum I.A., Lamartiniere C.A. Epigallocatechin-3-gallate suppresses early stage, but not late stage prostate cancer in TRAMP mice: mechanisms of action. Prostate 2007, 67:1576-1589.
38. Yue B., Zhang Y.S., Xu H.M., Zhao C.R., Li Y.Y., Qin Y.Z., et al. Riccardin D-26, a synthesized macrocyclic bisbibenzyl compound, inhibits human hepatocellular carcinoma growth through induction of apoptosis in p53-dependent way. Cancer Lett. 2013, 328:104-113.
39. Yamaguchi T., Yanagisawa K., Sugiyama R., Hosono Y., Shimada Y., Arima C., et al. NKX2-1/TITF1/TTF-1-induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer Cell 2012, 21:348-361.
40. Gentile A., Lazzari L., Benvenuti S., Trusolino L., Comoglio P.M. Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis. Cancer Res. 2011, 71:3132-3141.
41. Vousden K.H., Prives C. Blinded by the light: the growing complexity of p53. Cell 2009, 137:413-431.
42. Halberg R.B., Katzung D.S., Hoff P.D., Moser A.R., Cole C.E., Lubet R.A., et al. Tumorigenesis in the multiple intestinal neoplasia mouse: redundancy of negative regulators and specificity of modifiers. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:3461-3466.
43. Ahn B., Ohshima H. Suppression of intestinal polyposis in Apc(min/+) mice by inhibiting nitric oxide production. Cancer Res. 2001, 61:8357-8360.